natgillin/translations-raw huggingface dataset:
Kvinder må ikke blive gravide, mens de tager Vitekta.
Women must not get pregnant while taking Vitekta.
Kvinder Mænd
Female patients Male patients
Kvinder og ældre patienter kan være mere følsomme for lægemiddelrelaterede virkninger på QT- og/eller PR-intervallet.
Women and elderly patients may be more susceptible to drug-associated effects on the QT and/or PR interval.
kvinder patienter, der er smittet med hepatitis B eller hepatitis C
women infected with hepatitis B or C
Kvinder på mellem 16 og 26 år
16 to 26-year-old women
Kvinder på mellem 16 og 26 år
16 to 26-years of age women
Kvinder skal bruge en sikker præventionsmetode under behandling med OLYSIO.
Women must use an effective method of contraception during treatment with OLYSIO.
Kvinder skal bruge sikker prævention under behandlingen.
Women must use effective contraception during treatment.
Kvinder skal informere deres læge med det samme, hvis de stopper med at anvende antikonception, eller før de skifter antikonceptionsmetode.
To inform their doctor immediately if they stop contraception, or prior to changing contraceptive measures
Kvinder skal oplyses om, at orale præventionsmidler ikke beskytter mod hiv-infektioner (aids) og andre seksuelt overførte sygdomme.
Women should be advised that hormonal contraceptives do not protect against HIV infections (AIDS) and other sexually transmissible diseases.
Kvinder som gennemgår ovariestimulation med henblik på multipel follikeludvikling i forbindelse med in vitro fertilisation eller anden assisteret reproduktionsteknologi
Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilisation or other assisted reproductive technologies
Kvinder som gennemgår ovariestimulation med henblik på multipel follikeludvikling i forbindelse med in vitro fertilisation eller anden assisteret reproduktionsteknologi
Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilisation or other assisted reproductive technologies.
Kvinder som ikke har ægløsning
Women who are not ovulating
Kvinder synes at have en større risiko end mænd for udvikling af udslæt, hvad enten de får behandling indeholdende nevirapin eller ej.
Women appear to be at higher risk than men of developing rash, whether receiving nevirapine or non-nevirapine containing therapy.
Kvinder vaccineret med Gardasil i 16-23-års-alderen i protokol 015-basisstudiet vil blive fulgt i op til 14 år i et udvidet studie.
Women vaccinated with Gardasil at 16-23 years of age in Protocol 015 base study will be followed up to 14 years in an extension study.
Kvinder vaccineret med Gardasil i 24-45-års-alderen i protokol 019-basisstudiet vil blive fulgt i op til 10 år i et udvidet studie.
Women vaccinated with Gardasil at 24-45 years of age in Protocol 019 base study will be followed up to 10 years in an extension study.
Kvinder vaccineret med Silgard i 24-45-års-alderen i protokol 019-basisstudiet vil blive fulgt i op til 10 år i et udvidet studie.
Women vaccinated with Silgard at 24-45 years of age in Protocol 019 base study will be followed up to 10 years in an extension study.
Kvinder – brug prævention i 2 måneder efter.
Women – keep using contraception for 2 months after.
Kvinder, der ammer under behandling med Neulasta, opfordres til at deltage i Amgens amningsovervågningsprogram.
Women who are breast-feeding during Neulasta treatment are encouraged to enrol in Amgen’s Lactation Surveillance programme.
Kvinder, der ammer under behandling med Ristempa, opfordres til at deltage i Amgens amningsovervågningsprogram.
Women who are breast-feeding during Ristempa treatment are encouraged to enrol in Amgen’s Lactation Surveillance programme.
Kvinder, der ammer under behandling med XGEVA, opfordres til at deltage i Amgens amningsovervågningsprogram.
Women who are nursing during XGEVA treatment are encouraged to enrol in Amgen’s Lactation Surveillance Programme.
Kvinder, der ammer, må ikke tage denne medicin.
Breastfeeding women must not take this medicine.
Kvinder, der anvender Intrinsa, bør også tage østrogener, men ikke af den type, der er kendt som ‘konjugerede østrogener’, da disse ikke er lige så effektive i kombination med Intrinsa som med andre typer østrogen.
Women using Intrinsa should also use oestrogens, but not of the type known as ‘conjugated oestrogens’ because the combination of these with Intrinsa is not as effective as the combination of other types of oestrogen with Intrinsa.
Kvinder, der behandles med Tyverb, skal ophøre med at amme.
Breast-feeding must be discontinued in women who are receiving therapy with Tyverb.
Kvinder, der behandles med Volibris, skal informeres om risikoen for fosterskader.
That women receiving Volibris should be advised of the risk of foetal harm.
Kvinder, der bliver gravide under behandling med Neulasta, opfordres til at deltage i Amgens graviditetsovervågningsprogram.
Women who become pregnant during Neulasta treatment are encouraged to enrol in Amgen’s Pregnancy Surveillance Programme.
Kvinder, der bliver gravide under behandling med Ristempa, opfordres til at deltage i Amgens graviditetsovervågningsprogram.
Women who become pregnant during Ristempa treatment are encouraged to enrol in Amgen’s Pregnancy Surveillance Programme.
Kvinder, der bliver gravide under behandling med XGEVA, opfordres til at deltage i Amgens graviditetsovervågningsprogram.
Women who become pregnant during XGEVA treatment are encouraged to enrol in Amgen’s Pregnancy Surveillance Programme.
Kvinder, der bruger hormonelle præventionsmidler, skal også benytte en barrieremetode som supplement (f.eks. kondom eller pessar med sæddræbende creme).
Women using these types of hormonal contraceptives must also use a second ‘barrier’ method (such as condoms or diaphragm with spermicide).
Kvinder, der er gravide eller som prøver at blive gravide, bør ikke have med MabCampath at gøre.
Women who are pregnant or trying to become pregnant should not handle MabCampath.
kvinder, der er gravide,
women who are pregnant;
Kvinder, der er hiv-positive, må ikke amme deres børn, da hiv-infektionen kan overføres til barnet gennem mælken.
Women who are HIV-positive must not breast-feed because HIV infection can be passed on to the baby in breast milk.
Kvinder, der får Cancidas, må ikke amme.
Women given Cancidas should not breast-feed.
Kvinder, der får Caspofungin Accord, må ikke amme.
Women given Caspofungin Accord should not breast-feed.
Kvinder, der får Myocet, bør ikke amme.
Women having Myocet should not breast-feed.
Kvinder, der får Myocet, må ikke amme.
Women receiving Myocet should not breastfeed.
Kvinder, der gennemgår superovulation med henblik på assisteret befrugtning, fx in vitro fertilisering (IVF):
Women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF):
Kvinder, der i forvejen har hypertriglyceridæmi, bør følges nøje under behandling med østrogener, da der er rapporteret om sjældne tilfælde af store stigninger i plasmatriglycerider, som har ført til pankreatitis ved østrogenbehandling. .
Women with pre-existing hypertriglyceridaemia should be followed closely during treatment with oestrogens, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition.
Kvinder, der kan blive gravide, bør bruge sikker prævention såsom p-piller, pessar plus sæddræbende creme eller spiral under behandlingen og tre måneder efter at have fået det sidste SCENESSE- implantat.
Women who could become pregnant should use adequate contraception such as oral contraceptives, diaphragm plus spermicide, intrauterine device (also known as a coil) during treatment and for three months after the last SCENESSE implantation.
Kvinder, der kan blive gravide, skal anvende prævention under behandlingen med dulaglutid.
Women who could become pregnant should use contraception during treatment with dulagutide.
Kvinder, der kan blive gravide, skal anvende sikker prævention under behandling med Extavia.
Women who could become pregnant should use appropriate contraception during treatment with Extavia.
Kvinder, der kan blive gravide, skal bruge sikker prævention, mens de er i behandling med Nevanac.
Women who may become pregnant are advised to use effective contraception during NEVANAC treatment.
Kvinder, der kan få børn, skal benytte tilstrækkelig prævention, mens de får Yondelis og i 3 måneder efter, at behandlingen er afsluttet.
Adequate contraceptive precautions must be used by women of childbearing potential when receiving Yondelis and for 3 months following the end of treatment.
Kvinder, der tager Duavive, bør ikke tage syntetiske gestagener, yderligere østrogener eller selektive østrogenreceptormodulatorer.
Women taking DUAVIVE should not be taking progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs).
Kvinder, der tager Duavive, bør ikke tage yderligere østrogener, da dette kan øge risikoen for endometriehyperplasi og endometriekarcinom.
Women taking DUAVIVE should not take additional oestrogens as this may increase the risk of endometrial hyperplasia and endometrial carcinoma.
Kvinder, der tager IOA
Women using IOA
Kvinder, der tager Latuda, bør kun amme, hvis de potentielle fordele ved behandlingen, opvejer den potentielle risiko for det ammede barn.
Breast feeding in women receiving Latuda should be considered only if the potential benefit of treatment justifies the potential risk to the child.
Kvinder, der tager Marixino, bør ikke amme.
Women taking Marixino should not breast-feed.
Kvinder, der tager Memantine Mylan, bør ikke amme.
Women taking Memantine Mylan should not breast-feed.
Kvinder, der tager Nemdatine, bør ikke amme.
Women taking Nemdatine should not breast-feed.
Kvinder, der tager Zoely
Women using Zoely
Kvinder, som allerede var inficeret med en eller flere vaccine- relaterede HPV-typer forud for vaccination, var beskyttet imod klinisk sygdom forårsaget af de resterende vaccine-HPV-typer.
Women who were already infected with one or more vaccine-related HPV types prior to vaccination were protected from clinical disease caused by the remaining vaccine HPV types.
Kvinder, som ammer, mens de behandles med Prolia, opfordres til at deltage i Amgens amnings- overvågningsprogram.
Women who are breast-feeding during Prolia treatment are encouraged to enrol in Amgen’s lactation surveillance program.
Kvinder, som bliver gravide under behandling med Aranesp, opfordres til at deltage i Amgens graviditetsovervågningsprogram.
Women who become pregnant during Aranesp treatment are encouraged to enrol in Amgen’s Pregnancy Surveillance programme.
Kvinder, som bliver gravide, mens de behandles med Prolia, opfordres til at deltage i Amgens graviditetsovervågningsprogram.
Women who become pregnant during Prolia treatment are encouraged to enrol in Amgen’s pregnancy surveillance programme.
Kvinder, som bliver gravide, skal informeres om muligheden for, at fosteret kan tage skade.
Women who become pregnant should be advised of the possibility of harm to the fetus.
Kvinder, som er gravide, eller kvinder, som måske kan være gravide, skal anvende handsker, hvis det er nødvendigt, at de rører ved eller håndterer ZYTIGA.
Women who are pregnant or who may be pregnant should wear gloves if they need to touch or handle ZYTIGA.
Kvinder, som er gravide, som planlægger at blive gravide, eller som ammer, må ikke håndtere Xaluprine.
Women who are pregnant, planning to be or breastfeeding should not handle Xaluprine.
Kvinder, som er hiv-positive, må ikke amme deres børn, fordi hiv-infektionen kan overføres til barnet med mælken.
Women who are HIV-positive must not breast-feed, because HIV infection can be passed on to the baby in breast milk.
Kvinder, som fik Tyverb i kombination med capecitabin, overlevede gennemsnitligt i 75 uger, sammenlignet med 64,7 uger for dem, som fik capecitabin alene.
Women taking Tyverb with capecitabine survived for an average of 75 weeks, and those taking capecitabine alone survived for an average of 64.7 weeks.
Kvinder, som har været i behandling med canakinumab under graviditet, skal informeres om at oplyse dette til barnets sundhedsperson, før eventuelle vacciner gives til det nyfødte spædbarn.
Women who received canakinumab during pregnancy should be instructed to inform the baby’s healthcare professional before any vaccinations are given to their newborn infant.
kvinder, som ikke danner æg, og hos hvem behandling med clomifencitrat ikke virker (et andet lægemiddel, der stimulerer æggestokkene til at danne æg) kvinder, der er i behandling for barnløshed (fertilitetsbehandling) f.eks. ved hjælp af reagensglasbefrugtning.
women who do not produce eggs and do not respond to treatment with clomiphene citrate (another medicine that stimulates the ovaries to produce eggs);
Kvinder, som ikke tager en kombinations-p-pille og som ikke er gravide
Women who are not using a combined hormonal pill and are not pregnant
kvinder, som kan blive gravide
women who could become pregnant
Kvinder, som kan blive gravide, bør bruge sikker prævention under behandling med Myocet og i 6 måneder efter behandlingen.
Women who could get pregnant should use effective contraception during treatment with Myocet and for 6 months after treatment.
Kvinder, som kan blive gravide, skal benytte prævention for at forhindre dem i at blive gravide under behandlingen.
Women who could get pregnant should use contraception to stop them getting pregnant during treatment.
Kvinder, som tidligere har haft sygdom i æggestokkene, har risiko for graviditet, der udvikler sig uden for livmoderen (ektopisk graviditet), uanset om graviditet sker ved spontan befrugtning eller ved fertilitetsbehandling.
Women with a history of tubal disease are at risk of ectopic pregnancy (pregnancy where the embryo is implanted outside the womb), whether the pregnancy is obtained by spontaneous conception or with fertility treatments.
Kvinder, som var ældre end 36 år og vejede mindre end 50 kilogram, indgik ikke i studierne.
Women older than 36 years of age who weighed less than 50 kilograms were not studied.
Kvinder, ældre patienter, patienter med lav kropsvægt eller med moderat nyreinsufficiens (kreatininclearance 30 - <50 ml/min) kan have en øget blødningsrisiko.
Women, the elderly, patients with low body weight or with moderate renal impairment (creatinine clearance > 30 - < 50 ml/min) may have an increased risk of bleeding.
Kvinder: Amenorrhea, menorrhagi, menstruationsforstyrrelser, vaginallidelse, Mænd: Testikulær smerte
Female: amenorrhea, menorrhagia, menstrual disorder, vaginal disorder, Male: testicular pain
Kvinder: Dysmenoré
Female: dysmenorrhoea
Kvinderne fik desuden et ikke-hormonalt smøremiddel til skeden til anvendelse efter behov.
Women also received non-hormonal vaginal lubricant for use as needed.
Kvinderne havde forud for undersøgelsen ikke fået trastuzumab eller en aromatasehæmmer.
The women had not received trastuzumab or an aromatase inhibitor before entering this study.
Kvinderne skal informeres om straks at søge lægehjælp, hvis der opstår symptomer, og fortælle lægen eller sundhedspersonalet, at hun tager et kombineret hormonelt præventionsmiddel.
In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.
Kvinderne skal instrueres i, hvilke ændringer i deres bryster, der bør rapporteres til læge eller sundhedspersonale (se "Brystcancer" nedenfor).
Women should be advised what changes in their breasts should be reported to their doctor or nurse (see ‘Breast cancer’ below).
Kvinders frugtbarhed
Female fertility
Kvæg
Cattle.
Kvæg
Cattle:
Kvæg (kalve og ungkvæg) Hunde.
Cattle (calves and young cattle)\ Dogs
Kvæg (kalve og ungkvæg) og grise
Cattle (calves and young cattle) and pigs.
Kvæg (kalve og ungkvæg) og hunde.
Cattle (calves and young cattle) and dogs
Kvæg (kalve og ungkvæg) og svin.
Cattle (calves and young cattle) and pigs.
Kvæg (kalve og ungkvæg).
Cattle (calves and young cattle)
Kvæg (køer og kvier)
Cattle (cows and heifers).
Kvæg (lakterende malkekøer)
Cattle (lactating dairy cows)
Kvæg (malkekøer og kvier)
Cattle (dairy cows and heifers)
Kvæg (malkekøer).
Cattle (dairy cows)
Kvæg fra 2 ugers alderen: en dosis på 2 ml, subkutan administration.
Cattle from 2 weeks of age: one dose of 2 ml, by subcutaneous route.
Kvæg fra 2 ugersalderen: en dosis på 2 ml, subkutan administration.
Cattle from 2 weeks of age: one dose of 2 ml, by subcutaneous route.
Kvæg fra 3 måneder: Basisvaccination:
Cattle from 3 months of age:
Kvæg fra 3,5 måneders alderen: Administrer 2 doser på 2 ml med 3 ugers mellemrum.
For cattle from 3.5 months of age: administer two doses of 2 ml three weeks apart.
Kvæg fra 3,5 måneders alderen: Administrer 2doser på 2 ml med 3 ugers mellemrum.
For cattle from 3.5 months of age: administer two doses of 2 ml three weeks apart.
Kvæg Får
Cattle,
Kvæg Får
injection
Kvæg Får
Sheep
Kvæg Geder Svin Kanin Heste
Bovine, caprine, porcine, rabbit, Equidae
Kvæg Kød og slagteaffald: 15 dage, mælk: 5 dage
Cattle: meat and offal: 15 days; milk: 5 days
Kvæg og får
Sheep and cattle
Kvæg og får : subkutan administration.
Cattle and sheep: for subcutaneous use.
Kvæg og får.
Cattle and sheep
Kvæg og geder
Cattle and goats
Kvæg og grise
Cattle and pigs
Kvæg og grise
Cattle, pigs
Kvæg og heste
Cattle and horses.
Kvæg og heste
Cattle, and horses
Kvæg og hunde
Cattle and dogs
kvæg og svin
Cattle and pigs
Kvæg og svin
Cattle and pigs.
Kvæg og svin.
Cattle and pigs.
Kvæg s.c. eller i.v injektion.
Cattle: SC or IV injection.
Kvæg Æske
Cattle Box
Kvæg, får og svin.
Cattle, sheep, and pigs
Kvæg, får: s.c.
Cattle, sheep: SC.
Kvæg, geder, grise, kaniner, dyr af hestefami lien
Bovine, caprine, porcine, rabbit, Equidae
Kvæg, geder, grise, kaniner, dyr af hestefamilien
Bovine, caprine, porcine, rabbit, Equidae
Kvæg, grise
Cattle & Pigs
Kvæg, grise
Cattle and pigs
Kvæg, grise
Cattle,
Kvæg, grise
Cattle, Pigs
Kvæg, grise og heste
Cattle and pigs
Kvæg, grise og heste
Cattle, horses and pigs
Kvæg, grise og heste
Cattle, pigs and horses.
Kvæg, grise og heste.
Cattle, pigs and horses
kvæg, heste og svin
Cattle, pigs and horses
Kvæg, svin og får.
Cattle, pigs and sheep
Kvæg, svin og hest.
Cattle, pigs and horses
Kvæg, svin og heste
Cattle, Horse and Pig
Kvæg, svin og heste.
Cattle, pigs and horses
Kvæg, svin,
Cattle,
Kvæg, svin, får
Cattle, pigs and sheep
Kvæg, svin, hest
Cattle, pigs, horses
Kvæg, svin, heste
Cattle, pigs and horses.
Kvæg2
Bovine2
Kvæg:
Cattle
Kvæg: 46 dage
Cattle: 46 days
Kvæg: 50, 100 og 250 ml hætteglas.
Cattle: 50, 100 and 250 ml vials.
Kvæg: En enkelt subkutan eller intravenøs injektion.
Cattle: Single subcutaneous or intravenous injection.
Kvæg: Enkelt s.c. eller i.v injektion.
Cattle: Single S.C. or I.V. injection.
Kvæg: intramuskulær anvendelse.
Cattle: intramuscular use.
Kvæg: Kan anvendes under drægtighed og laktation.
Cattle: Can be used during pregnancy and lactation.
Kvæg: kød og
Cattle: meat and
Kvæg: kød og indmad: 15 dage
Cattle: meat and offal: 15 days
Kvæg: Kød og indmad: 15 dage, Mælk: 5 dage
Cattle: Meat and offal: 15 days; Milk: 5 days
Kvæg: kød og indmad: 15 dage; mælk: 5 dage
Cattle: Meat and offal: 15 days Milk: 5 days
Kvæg: kød og indmad: 15 dage; mælk: 5 dage
Cattle: meat and offal: 15 days; milk: 5 days
Kvæg: kød og indmad: 15 dage; mælk: 5 dage
Cattle: meat and offal: 15 days; milk: 5 days.
Kvæg: kød og indmad: 15 dage; mælk: 5 dage Grise, heste: kød og indmad: 5 dage
Cattle: meat and offal: 15 days; milk: 5 days Pigs, horses: meat and offal: 5 days
Kvæg: Kød og indmad: 15 dage; mælk: 5 dage.
Cattle: Meat and offal: 15 days; milk: 5 days.
Kvæg: kød og indvolde: 15 dage
Cattle: meat and offal: 15 days
Kvæg: kød og indvolde: 15 dage
Cattle: meat and offal: 15 days.
Kvæg: Kød og indvolde: 15 dage,
Meat and offal: 15 days (Cattle), Milk: 5 days (Cattle),
Kvæg: Kød og indvolde: 15 dage; Mælk: 5 dage
Cattle: meat and offal: 15 days; milk: 5 days
Kvæg: kød og indvolde: 15 dage; mælk: 5 dage
Cattle: meat and offal: 15 days; milk: 5 days.
Kvæg: Kød og slagteaffald: 15 dage, mælk: 5 dage
Cattle: meat and offal: 15 days; milk: 5 days
Kvæg: QI02AA08
Cattle: QI02AA08
Kvæg: s.c.
Cattle: SC
Kvæg: s.c.
Cattle: SC.
Kvæg: s.c. eller i.v injektion.
Cattle: SC or IV injection.
Kvæg: s.c. eller i.v.
Cattle: SC or IV
Kvæg: s.c. eller i.v. injektion.
Cattle: SC or IV injection.
Kvæg: s.c., i.v.
Cattle: S.C., I.V.
Kvæg: s.c., i.v.
Cattle: SC ,IV
Kvæg: s.c., i.v.
Cattle: SC, IV
Kvæg: s.c.eller i.v.
Cattle: SC or IV
Kvæg: s.c.eller i.v.
Cattle: SC or IV.
Kvæg: SC, IV Svin: IM Heste: IV
Cattle: SC, IV Pigs: IM Horses: IV
Kvæg: slagtning: 15 dage
Cattle: meat and offal: 15 days
Kvæg: slagtning: 15 dage; mælk: 5 dage
Cattle: meat and offal: 15 days; milk: 5 days
Kvæg: Slagtning: 15 døgn; Mælk: 5 døgn Svin: Slagtning: 5 døgn
Cattle: Meat and offal: 15 days; Milk: 5 days Pigs: Meat and offal: 5 days
Kvæg: Subkutan
Cattle:
Kvæg: Subkutan
Cattle: subcutaneous injection;
Kvæg: Subkutan brug, intravenøs brug.
Cattle: subcutaneous use, intravenous use.
Kvæg: Subkutan eller intravenøs anvendelse Grise: Intramuskulær anvendelse
Cattle: Subcutaneous or intravenous use Pigs: Intramuscular use
Kvæg: subkutan eller intravenøs anvendelse Grise: intramuskulær brug
Cattle: subcutaneous or intravenous use Pigs: intramuscular use
Kvæg: Subkutan eller intravenøs injektion Svin: Intramuskulær injektion
Cattle: Subcutaneous or Intravenous use Pigs: Intramuscular use
Kvæg: Subkutan injektion.
Cattle: subcutaneous injection.
Kvæg: Subkutan injektion;
Cattle: subcutaneous injection
Kvæg: Subkutan injektion;
Cattle: subcutaneous injection;
Kvæget kan desuden vise tegn på let smerte på injektionsstedet i én dag.
The cattle may also show some signs of slight pain at the site of injection for one day.
kvælningsfornemmelse
choking sensation
Kvælstof er en af byggestenene i proteiner, og derfor ophobes der kvælstof i kroppen, når man har indtaget proteiner.
Nitrogen is a building block of proteins, because of this there is a build up of nitrogen in the body after eating protein.
kvæstelse i hovedet
a head injury
KwikPen (“Pen”) er en fyldt éngangspen, der indeholder 3 ml (300 enheder, 100 enheder/ml) insulin.
KwikPen (“Pen”) is a disposable pre-filled pen containing 3ml (300 units, 100 units/ml) of insulin.
KwikPen anbefales til brug sammen med nåle fra Becton, Dickinson and Company (BD).
KwikPen is recommended for use with Becton, Dickinson and Company (BD) pen needles.
KwikPen Flerstykspakning: 10 (2 pakninger a 5) penne a 3 ml.
KwikPen Multipack: 10 (2 packs of 5) pens of 3 mL.
KwikPen indeholdende din insulin
KwikPen containing your insulin
KwikPen ”fyldt insulin pen” 100 enheder/ml
KwikPen pre-filled insulin pen 100 units/ml
KwikPen  Ny nål  Desinfektionsserviet
KwikPen  New Pen Needle
KwikPen. (injektion).
KwikPen. (Injection).
KwikPennen indeholder det samme Humalog BASAL, som findes i løse Humalog BASAL cylinderampuller.
The Humalog BASAL in your KwikPen is the same as the Humalog BASAL, which comes in separate Humalog BASAL cartridges.
KwikPennen indeholder det samme Humalog Mix25, som findes i løse Humalog Mix25 cylinder- ampuller.
The Humalog Mix25 in your KwikPen is the same as the Humalog Mix25, which comes in separate Humalog Mix25 cartridges.
KwikPennen indeholder det samme Humalog Mix50, som findes i løse Humalog Mix50 cylinder- ampuller.
The Humalog Mix50 in your KwikPen is the same as the Humalog Mix50, which comes in separate Humalog Mix50 cartridges.
KwikPennen indeholder det samme Liprolog Basal, som findes i løse Liprolog Basal cylinderampuller.
The Liprolog Basal in your KwikPen is the same as the Liprolog Basal, which comes in separate Liprolog Basal cartridges.
KwikPennen indeholder det samme Liprolog Mix25, som findes i løse Liprolog Mix25 cylinder- ampuller.
The Liprolog Mix25 in your pre-filled pen is the same as the Liprolog Mix25, which comes in separate Liprolog Mix25 cartridges.
KwikPennen indeholder det samme Liprolog Mix50, som findes i løse Liprolog Mix50 cylinder- ampuller.
The Liprolog Mix50 in your pre-filled pen is the same as the Liprolog Mix50, which comes in separate Liprolog Mix50 cartridges.
Kwikpennen indeholder en indbygget cylinderampul.
The KwikPen simply has a built in cartridge.
KwikPennen™ er designet, så den er let at bruge.
The KwikPen™ is designed for ease of use.